US Bancorp’s Calithera Biosciences, Inc CALA Stock Holding History

US Bancorp’s Portfolio CALA Stock Details CALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-85	Closed	-$9K	–	3919
2020 Q2	$9K	Buy	+85	New	+$10.1K	﹤0.01%	3145

Other funds holding CALA

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

US Bancorp's CALA Position: Q3 2020 in Review

US Bancorp sold out of Calithera Biosciences, Inc (CALA) in Q3 2020, closing a stake of 85 shares — an estimated $9K sold.

US Bancorp first reported a position in CALA in Q2 2020 and held it in 1 quarter. The position peaked at $9K in Q2 2020. 97 funds tracked by Wall St. Rank hold CALA as of Q3 2020.

US Bancorp reported no remaining Calithera Biosciences, Inc position as of Q3 2020 after selling out during the quarter.
US Bancorp sold 85 Calithera Biosciences, Inc shares in Q3 2020, an estimated $9K.
US Bancorp first reported a position in Calithera Biosciences, Inc in Q2 2020 and held it in 1 quarter.
US Bancorp's Calithera Biosciences, Inc position peaked at $9K in Q2 2020.
97 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q3 2020.

Based on US Bancorp's 13F filing for Q3 2020, filed 10 Nov 2020.